717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Bibliographic Details
Main Authors: Caius Radu, Mark Salvati, Julie Bailis, Katharina Lueckerath, Kyle Current, Johannes Czernin
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-3c9fc4255283428fb7568663820bf4f8
record_format Article
spelling doaj-3c9fc4255283428fb7568663820bf4f82020-12-11T10:03:36ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0717717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapyCaius Radu0Mark Salvati1Julie Bailis2Katharina Lueckerath3Kyle Current4Johannes Czernin51David Geffen School of Medicine at UCLA, Los Angeles, CA, USA2Amgen Inc., San Francisco, CA, USA2Amgen Inc., San Francisco, CA, USA1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
collection DOAJ
language English
format Article
sources DOAJ
author Caius Radu
Mark Salvati
Julie Bailis
Katharina Lueckerath
Kyle Current
Johannes Czernin
spellingShingle Caius Radu
Mark Salvati
Julie Bailis
Katharina Lueckerath
Kyle Current
Johannes Czernin
717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
Journal for ImmunoTherapy of Cancer
author_facet Caius Radu
Mark Salvati
Julie Bailis
Katharina Lueckerath
Kyle Current
Johannes Czernin
author_sort Caius Radu
title 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
title_short 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
title_full 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
title_fullStr 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
title_full_unstemmed 717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
title_sort 717 amg 160, a prostate-specific membrane antigen (psma)-targeted bite® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT caiusradu 717amg160aprostatespecificmembraneantigenpsmatargetedbiteimmunooncologytherapyisactiveinmodelsofadvancedprostatecancerthatareresistanttoradioligandtherapy
AT marksalvati 717amg160aprostatespecificmembraneantigenpsmatargetedbiteimmunooncologytherapyisactiveinmodelsofadvancedprostatecancerthatareresistanttoradioligandtherapy
AT juliebailis 717amg160aprostatespecificmembraneantigenpsmatargetedbiteimmunooncologytherapyisactiveinmodelsofadvancedprostatecancerthatareresistanttoradioligandtherapy
AT katharinalueckerath 717amg160aprostatespecificmembraneantigenpsmatargetedbiteimmunooncologytherapyisactiveinmodelsofadvancedprostatecancerthatareresistanttoradioligandtherapy
AT kylecurrent 717amg160aprostatespecificmembraneantigenpsmatargetedbiteimmunooncologytherapyisactiveinmodelsofadvancedprostatecancerthatareresistanttoradioligandtherapy
AT johannesczernin 717amg160aprostatespecificmembraneantigenpsmatargetedbiteimmunooncologytherapyisactiveinmodelsofadvancedprostatecancerthatareresistanttoradioligandtherapy
_version_ 1724386546431295488

Similar Items